Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1015

Trial Profile

A First-in-human, Multicenter, Open-label, Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of Intravenously Administered ATOR-1015

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs ATOR-1015 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Alligator Bioscience
  • Most Recent Events

    • 30 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 19 Dec 2018 Status changed from planning to not yet recruiting.
    • 11 Dec 2018 According to an Alligator Bioscience media release, regulatory approvals have been obtained for this study and patient recruitment can now be initiated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top